CD79A and diffuse large B-cell lymphoma: Studies have shown that when CD20 is lost, the retention of other B-cell markers such as CD19, CD79a, and PAX5 can still indicate the underlying B-cell malignancy and guide appropriate therapeutic decisions, particularly in cases like DLBCL, where treatment outcomes may vary based on the lineage determined [20].